Type 2 DM is associated with an increased risk of GC among patients in whom HP was eradicated, in particular those with gastric cardia cancer and those with suboptimal DM control (Diabetes Care)
Diabetes News
Tag: cancer
Worldwide burden of cancer attributable to diabetes and high body-mass index: a comparative risk assessment
A substantial number of cancer cases are attributable to diabetes and high BMI. As the prevalence of these cancer risk factors increases, clinical and public health efforts should focus on identifying optimal preventive and screening measures for whole populations and individual patients (The Lancet Diabetes & Endocrinology)
Metformin Improves Overall Survival of Colorectal Cancer Patients with Diabetes: A Meta-Analysis
Metformin prolongs the overall survival of diabetic colorectal cancer patients, but it does not affect the colorectal cancer-specific survival. Metformin may be a good choice in treating colorectal cancer patients with diabetes mellitus in clinical settings (Journal of Diabetes Research)
Use of statins offsets insulin-related cancer risk
The use of statins offsets insulin-related cancer risks in patients with diabetes independently of sex and age (Journal of Internal Medicine)
Use of statins offsets insulin-related cancer risk
The use of statins offsets insulin-related cancer risks in patients with diabetes independently of sex and age. Overall, our data support the hyperglycaemia–cancer hypothesis. A reduction in endogenous or exogenous hyperinsulinaemia may be beneficial for cancer prevention. Therefore, insulin-sparing and insulin-sensitizing drugs should be the preferred treatment choices (Journal of Internal Medicine)
Cancer risk in patients aged 30 years and above with type 2 diabetes receiving antidiabetic monotherapy: a cohort study using metformin as the comparator
Metformin monotherapy may be associated with a reduction in the risk for cancer development compared with sulfonylurea monotherapy. Moreover, the use of an average defined daily dose of >0.25 of metformin when compared to lower dose will contribute to a reduction of 80% risk (Therapeutics and Clinical Risk management)
Use of an α-Glucosidase Inhibitor and the Risk of Colorectal Cancer in Patients With Diabetes: A Nationwide, Population-Based Cohort Study
Acarbose use reduced the risk of incident colorectal cancer in patients with diabetes in a dose-dependent manner (Diabetes Care)
Pioglitazone and bladder cancer risk: a multipopulation pooled, cumulative exposure analysis
The cumulative use of pioglitazone or rosiglitazone was not associated with the incidence of bladder cancer in this large, pooled multipopulation analysis (Diabetologia)
Impact of diabetes type II and chronic inflammation on pancreatic cancer
We conclude that diabetes type II has a fundamental influence on pancreatic ductal adenocarcinoma by stimulating cancer cell proliferation, while metformin inhibits cancer cell proliferation (BMC Cancer)
Type 2 diabetes and cancer: umbrella review of meta-analyses of observational studies
Though type 2 diabetes has been extensively studied in relation to risk of developing cancer and cancer mortality and strong claims of significance exist for most of the studied associations, only a minority of these associations have robust supporting evidence without hints of bias (BMJ)
Glycosmedia is also available as an App: